One analyst forecasts a $470 million loss over the next two years on Boston Scientific's defibrillator recall, while others say the company could look to sell off its pain management or neurovascular intervention units to cover the gap.

Boston Scientific Corp. (NYSE:BSX) could look to sell of a business unit to make up for a projected $470 million shortfall stemming from the shutdown of its defibrillator operation, according to analysts.
Pluristem is seeking clinical proof that stem cell therapy can benefit patients with chronic...
GE Healthcare introduces Mavric SL, a novel magnetic resonance imaging technique for joint...
Johnson & Johnson subsidiary DePuy Orthopaedics plans to phase out sales of all of its metal-on-...
The FDA approves a novel combat-ready clamp to treat wounds most commonly associated with roadside or...
Vascular Solutions CEO Howard Root says alleged infringement by Boston Scientific's Guidezilla "is...